Bausch Health Companies Inc. (NYSE:BHC) marched up 38.78% compared to a 52-week low price of $17.2. The shares were last seen trading -4.21% lower, taking the closing price at $23.87 on 7/11/2019. At a recent session, the prices were hovering between $23.6 and $24.99. This company shares are 29.58% off its target price of $30.93 and the current market capitalization stands at $8.39B. The recent change has given its price a 0.9% lead over SMA 50 and -16.1% deficit over its 52-week high. The stock witnessed 7.86% gains, -8.61% declines and 2.31% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BHC’s volatility during a week at 3.22% and during a month it has been found around 3.24%.

What Does Bausch Health Companies Inc. (BHC) Do?

The company describes itself in regulatory filings as, “Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.” [Text can be found here: https://www.marketwatch.com/investing/stock/BHC/profile under company description.]

Bausch Health Companies Inc. (BHC) Top Holders

Institutional investors currently hold around $4.79 billion or 66.8% in BHC stock. Look at its top three institutional owners: Paulson & Co. Inc. owns $519.31 million in Bausch Health Companies Inc., which represents roughly 6.19% of the company’s market cap and approximately 10.84% of the institutional ownership. Similar statistics are true for the second largest owner, Valueact Holdings, L.P., which owns 18,033,149 shares of the stock are valued at $449.39 million. The third largest holder is Fil Ltd, which currently holds $262.79 million worth of this stock and that ownership represents nearly 3.13% of its market capitalization.

Bausch Health Companies Inc. 13F Filings

At the end of March reporting period, 149 institutional holders increased their position in Bausch Health Companies Inc. (NYSE:BHC) by some 24,309,976 shares, 156 decreased positions by 23,883,886 and 76 held positions by 144,012,211. That puts total institutional holdings at 192,206,073 shares, according to SEC filings. The stock grabbed 47 new institutional investments totaling 5,224,160 shares while 38 institutional investors sold out their entire positions totaling 5,105,912 shares.

Bausch Health Companies Inc. (NYSE:BHC) Insider Trades

Multiple company employees have indulged in significant insider trading. Bausch Health Companies Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CHAIRMAN & CEO PAPA JOSEPH C has acquired 30,000 shares of Bausch Health Companies Inc. (BHC) in the trading session dated Feb. 28, 2019. These shares are worth $710,100 and were traded at $23.67 each. The SEC filing shows that APPIO THOMAS performed a purchase of 25,440 shares. The Pres&Co-Head Bausch&Lomb/Int’l added these shares by way of transaction on Dec. 14, 2018. The company’s shares were assimilated at $22.96 per share worth to an investment of some $584,102 to the account of APPIO THOMAS.

EVP AND GENERAL COUNSEL, ACKERMANN CHRISTINA, sold 19,946 common shares of Bausch Health Companies Inc. (BHC) in the open market. In a transaction dated Oct. 16, 2018, the shares were put up for sale at an average price of $24.98, raking in a sum of $498,251. After this sale, 51,456 common shares of BHC are directly owned by the insider, with total stake valued at $1,228,255.

In the transaction dated Sep. 14, 2018, a great number of shares acquired came courtesy the CHAIRMAN & CEO; PAPA JOSEPH C added a total of 30,000 shares at an average price of $22.32, amounting to approximately $669,600. The insider now directly owns 687,077 shares worth $16,400,528.

Bausch Health Companies Inc. (BHC) Analyst Guide

Several analysts have released their opinion on Bausch Health Companies Inc. (NYSE:BHC), with 2 analysts believing it is a strong buy. Whereas 6 of them predict the stock is a hold. Also, there are 7 buy, 2 sell and 0 strong sell ratings, collectively assigning a 2.47 average brokerage recommendation [T1].